Radiology Partners' Cognita Chest X-ray AI tool earns FDA Breakthrough Device status for multiple clinical uses.
Key Details
- 1Radiology Partners' Cognita business received FDA Breakthrough Device designation for its Chest X-ray AI tool.
- 2The tool uses a generative vision-language model to assist radiologists in X-ray interpretation.
- 3This is among the first vision-language AI solutions in radiology to receive this designation.
- 4Breakthrough status expedites regulatory review for devices addressing critical needs.
- 5Cognita CXR integrates into radiology workflows to generate comprehensive preliminary reports for physician review.
Why It Matters
FDA Breakthrough Device designation is a major step for AI-driven radiology tools, signaling both clinical promise and regulatory progress. This can accelerate the path toward broader clinical deployment of advanced AI models in everyday radiology practice.
Source
Radiology Business
Related News
•AuntMinnie
AI Advances in Breast Cancer Risk, CEUS Training Updates, and Imaging AI Variability
This week's top radiology news reviews AI advances in breast and lung cancer risk prediction, new CEUS training standards, and prostate screening updates with imaging modalities.
•Radiology Business
Cloud-Native AI Architectures Drive Efficiency in Radiology
Cloud-native AI systems are advancing radiology by improving workflow integration, scalability, and software management.
•Radiology Business
DeepHealth's Prostate AI Gains FDA Clearance for MRI Workflows
DeepHealth, a RadNet subsidiary, received FDA clearance for its AI solution to assist prostate cancer detection and MRI workflow.